Povetacicept ( DrugBank: - )
3 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 61 | 自己免疫性溶血性貧血 | 1 |
| 63 | 特発性血小板減少性紫斑病 | 1 |
| 222 | 一次性ネフローゼ症候群 | 1 |
61. 自己免疫性溶血性貧血
臨床試験数 : 146 / 薬物数 : 131 - (DrugBank : 59) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05757570 (ClinicalTrials.gov) | May 2023 | 24/2/2023 | An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias | A Phase 1b Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4) | Immune Thrombocytopenia;Idiopathic Thrombocytopenic Purpura;Warm Autoimmune Hemolytic Anemia;Cold Agglutinin Disease | Drug: povetacicept | Alpine Immune Sciences, Inc. | NULL | Not yet recruiting | 18 Years | N/A | All | 42 | Phase 1 | NULL |
63. 特発性血小板減少性紫斑病
臨床試験数 : 391 / 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05757570 (ClinicalTrials.gov) | May 2023 | 24/2/2023 | An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias | A Phase 1b Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4) | Immune Thrombocytopenia;Idiopathic Thrombocytopenic Purpura;Warm Autoimmune Hemolytic Anemia;Cold Agglutinin Disease | Drug: povetacicept | Alpine Immune Sciences, Inc. | NULL | Not yet recruiting | 18 Years | N/A | All | 42 | Phase 1 | NULL |
222. 一次性ネフローゼ症候群
臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05732402 (ClinicalTrials.gov) | March 2023 | 8/2/2023 | An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases | An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3) | Lupus Nephritis;Immunoglobulin A Nephropathy;Membranous Nephropathy | Drug: povetacicept | Alpine Immune Sciences, Inc. | NULL | Not yet recruiting | 18 Years | N/A | All | 42 | Phase 1 | NULL |